© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#EASL 2014
Click Here for More Conferences
Click Here for EASL.eu
An Introduction to Hepatitis

Curing Hepatitis C Lowers Central Nervous System Fatigue

Curing hepatitis C reduces central fatigue, which is weakness originating in the central nervous system.

Sovaldi and Ribavirin Effectively Treat Genotype 4 of Hep C

Twenty-four weeks of Gilead Sciences’ Sovaldi and ribavirin boasted high cure rates among people with genotype 4 of hep C in a recent trial.

How Can Hep C Treatment Be Used to Prevent Its Spread?

The prospect of significantly slowing the spread of hepatitis through treatment has become an exciting prospect as therapy outcomes have...

Proof That Interferon Is a Major Drag

Interferon, along with depression and fatigue, is an independent variable that dampens the experience of hepatitis C treatment.

AbbVie ‘3D’ Regimen Highly Effective for Transplantees

AbbVie’s ’3-D’ regimen has had nearly perfect preliminary results in curing people with recurrent geno 1 of hep C post-liver transplant.

Sovaldi Can Cure Hep C Recurrence After Liver Transplant

Sovaldi treatment has shown good results curing those who have recurring hepatitis C following a liver transplant.

MUST read

Hepatitis C: The Basics
Hepatitis B: The Basics
Hepatitis A: The Basics

Sovaldi/Olysio Combo Cures 94% of Those With Liver Disease

Sovaldi and Olysio cured 94 percent of people who had genotype 1 of hepatitis C and advanced liver disease in a recent trial.

Faldaprevir, Deleobuvir & PPI-668 Combo Boasts High Cure Rate

Faldaprevir and deleobuvir plus Presidio’s PPI-668 cured 92 percent of those with genotype 1a of hepatitis C virus when given with riba...

High Cure Rates for Eight-Week Sovaldi/Ledipasvir Treatment

Eight weeks of the fixed-dose combination tablet of Sovaldi and ledipasvir can cure over 90 percent of non-cirrhotic people with genotype 1 of...

AbbVie’s ‘3-D’ Combo Cures 92-96% of Cirrhotic Genotype 1s

In a large trial, AbbVies ’3-D’ combination therapy cured 92 percent to 96 percent of cirrhotic study participants with geno 1 of hep C.

Sovaldi/Ledipasvir Pill Cures 94-99% of Genotype 1s

Gilead Sciences’ fixed-dose combination pill of Sovaldi and ledipasvir cured 94 percent to 99 percent of those with genotype 1 of hepat...

Hot topics

Forums: Support and discussion
Blogs: The community speaks

Viral Hepatitis Kills More Europeans Than HIV by Tenfold

European Union citizens die as a result of viral hepatitis at a rate about 10 times greater than deaths related to HIV.

Perfect HIV/HCV Coinfection Cure Rate for Sovaldi/Ledipasvir

A fixed-dose combo pill of Sovaldi and ledipasvir is poised to boast a 100 percent success rate in curing hepatitis C among those coinfected w...

AbbVie Cocktail Cures 96% of Those With Hep C Genotype 1

The AbbVie ’3-D’ regimen cured 96 percent of people who had genotype 1 of hepatitis C and did not have cirrhosis.

24 Weeks of Daclatasvir & Asunaprevir Cures 82-90% of 1b’s

BMS?s daclatasvir and asunaprevir cured between 82 to 90 percent of people with genotype 1b of hepatitis C.

Excellent Results Across Genotypes for Sovaldi and GS-5816

Sovaldi and GS-5816 cured about 95 percent of treatment-naive people with genotypes 1 through 6 of hepatitis C who did not have cirrhosis in a...
Advertisement
Science News
Newsfeed
Features
Ask Hep